New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients ...

The MarketWatch News Department was not involved in the creation of this content. METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial ...

A new study from researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain ...

Researchers reported at the 2026 European Lung Cancer Congress that Hernexeos (zongertinib) led to high response rates and ...

Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...

The primary battleground in the competition for lung cancer treatments is shifting toward "brain metastasis." This shift comes as new research has ...

Radiopharm Theranostics (NASDAQ:RADX) executives and clinical investigators highlighted new interim findings from the company ...

A team from the Spanish National Cancer Research Centre (CNIO) has discovered a novel way in which tumor cells alter the ...

Radiopharm Theranostics (NASDAQ:RADX) announced interim findings from its Phase 2b clinical trial evaluating RAD 101, an ...

RAD 101 and evaluable at interim analysis achieved concordance with MRI imaging (the primary endpoint)First five ...

METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields therapy and best supportive care following ...